These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
36. Anomalous growth of Staphylococcus epidermidis in the presence of Silastic and glycopeptide antibiotics. Hamilton-Miller JM; Shah S; Smith C FEMS Microbiol Lett; 1993 Oct; 113(2):145-7. PubMed ID: 8262364 [TBL] [Abstract][Full Text] [Related]
37. Biofilm testing of Staphylococcus epidermidis clinical isolates: low performance of vancomycin in relation to other antibiotics. Monzón M; Oteiza C; Leiva J; Lamata M; Amorena B Diagn Microbiol Infect Dis; 2002 Dec; 44(4):319-24. PubMed ID: 12543535 [TBL] [Abstract][Full Text] [Related]
38. Susceptibility Profile of Staphylococcus epidermidis and Staphylococcus haemolyticus Isolated from Blood Cultures to Vancomycin and Novel Antimicrobial Drugs over a Period of 12 Years. Pinheiro L; Brito CI; Pereira VC; Oliveira A; Bartolomeu AR; Camargo CH; Cunha ML Microb Drug Resist; 2016 Jun; 22(4):283-93. PubMed ID: 26623676 [TBL] [Abstract][Full Text] [Related]
39. Glycopeptide resistance in Staphylococcus haemolyticus during treatment with teicoplanin. Blans M; Troelstra A Infect Control Hosp Epidemiol; 2001 May; 22(5):263-4. PubMed ID: 11428432 [No Abstract] [Full Text] [Related]
40. In vitro antimicrobial activity of imipenem in combination with vancomycin or teicoplanin against Staphylococcus aureus and Staphylococcus epidermidis. Barr JG; Smyth ET; Hogg GM Eur J Clin Microbiol Infect Dis; 1990 Nov; 9(11):804-9. PubMed ID: 2150814 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]